Allarity Therapeutics Stock (NASDAQ:ALLR)

Revenue Ownership Financials Chart

Previous Close

$1.03

52W Range

$0.90 - $348.00

50D Avg

$1.31

200D Avg

$31.13

Market Cap

$4.39M

Avg Vol (3M)

$452.09K

Beta

0.29

Div Yield

ALLR Company Profile

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 21, 2021

Website

ALLR Performance

ALLR Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-20.42M	$-34.46M	$-26.56M
Net Income	$-20.42M	$-16.06M	$-26.65M
EBITDA	$-20.42M	$-16.80M	$-28.27M
Basic EPS	$-0.01	$-2.06	$-167.62
Diluted EPS	$-0.01	$-2.06	$-167.62

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
PHIO	Phio Pharmaceuticals Corp.
BDRX	Biodexa Pharmaceuticals Plc
CNSP	CNS Pharmaceuticals, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
VRAX	Virax Biolabs Group Limited
IMMX	Immix Biopharma, Inc.
ZURA	Zura Bio Limited
SONN	Sonnet BioTherapeutics Holdings, Inc.